Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Lunai Bioworks (Nasdaq:LNAI) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq staff had notified the company on April 14, 2025 that LNAI's common stock failed to maintain a $1.00 minimum bid over the prior 30 business days. Staff determined the closing bid price was at or above $1.00 for 11 consecutive business days from September 30, 2025 through October 14, 2025, restoring compliance and leaving the company eligible to remain listed on The Nasdaq Capital Market. Management said the milestone supports its focus on advancing an AI-powered platform for drug discovery and biodefense.

Positive

• Regained Nasdaq compliance after 11 consecutive business days at or above $1.00
• Remains eligible for continued listing on The Nasdaq Capital Market

Negative

• Notified on April 14, 2025 of prior failure to maintain $1.00 minimum bid

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement.

On April 14, 2025, Nasdaq Staff notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Listing Rule 5550(a)(2). However, Staff has since determined that for the 11 consecutive business days from September 30, 2025 through October 14, 2025, the closing bid price of Lunai Bioworks' common stock was at or above $1.00 per share. As a result, the Company has now regained compliance with the rule and remains eligible for continued listing on The Nasdaq Capital Market.

"This compliance milestone reflects our commitment to strategic execution and shareholder value during a transformative period for Lunai Bioworks," said David Weinstein, Chief Executive Officer. "We remain focused on advancing our AI-powered platform and delivering long-term impact across drug discovery and biodefense."

About Lunai Bioworks

Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.

Media Contact:

David Weinstein
Chief Executive Officer
305-918-1980
ir@lunaibioworks.com
http://www.lunaibioworks.com/

SOURCE: Lunai Bioworks Inc.

View the original press release on ACCESS Newswire

FAQ

When did Lunai Bioworks (LNAI) regain Nasdaq minimum bid price compliance?

Lunai Bioworks regained compliance after 11 business days from September 30, 2025 through October 14, 2025.

What Nasdaq rule did LNAI fail to meet earlier in 2025?

LNAI failed to meet Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement, per a notice on April 14, 2025.

Does Lunai Bioworks remain listed on Nasdaq after regaining compliance?

Yes. Staff determined the company met the minimum bid requirement and it remains eligible for continued listing on The Nasdaq Capital Market.

How long was the compliance run that restored LNAI's Nasdaq status?

The documented compliance run was 11 consecutive business days with closing bid prices at or above $1.00.

What period triggered Nasdaq's noncompliance notice for LNAI in April 2025?

Nasdaq staff notified LNAI on April 14, 2025 that the stock had failed to maintain a $1.00 minimum over the prior 30 consecutive business days.